SCHEMBL6569744

SCHEMBL6569744

Cc1ccc(O)c(/C=N\NC(=O)c2ccccc2)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 3/20 0.62
MAPT P10636 3/20 0.61
KDM4E B2RXH2 3/20 0.60
HTT P42858 3/20 0.60
RAB9A P51151 3/20 0.60
LMNA P02545 2/20 0.60
ALDH1A1 P00352 1/20 0.60
TP53 P04637 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
KDM1A O60341 4/20 0.59
MAOA P21397 1/20 0.58
MAOB P27338 1/20 0.58
KCNMA1 Q12791 1/20 0.57
NPC1 O15118 2/20 0.57
ALPL P05186 1/20 0.57
GLA P06280 1/20 0.57
ALPI P09923 1/20 0.57
ALPG P10696 1/20 0.57
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684973 1.00 PIK3CG (0.62) PIK3CGMAPTKDM4EHTTRAB9A
SCHEMBL6569747 1.00 PIK3CG (0.62) PIK3CGMAPTKDM4EHTTRAB9A
SCHEMBL685060 0.92 MAPT (0.72) PIK3CGMAPTKDM4EHTTRAB9A
SCHEMBL685021 0.90 KDM1A (0.61) PIK3CGMAPTKDM4EHTTRAB9A
SCHEMBL683909 0.89 PIK3CG (0.66) PIK3CGMAPTKDM4EHTTRAB9A
SCHEMBL684807 0.88 MAPT (0.64) PIK3CGMAPTKDM4EHTTRAB9A
SCHEMBL685064 0.86 KDM1A (0.72) PIK3CGMAPTKDM4EHTTRAB9A
SCHEMBL19965934 0.86 L3MBTL1 (0.73) MAPTKDM4EHTTRAB9ALMNA
SCHEMBL26974369 0.86 RAB9A (0.73) PIK3CGMAPTKDM4EHTTRAB9A
SCHEMBL12387736 0.86 GCGR (0.62) PIK3CGMAPTKDM4EHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO PIK3CG 1404/4885MAPT 3140/4885KDM4E 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.